Aafke E. Gaartman

Aafke E. Gaartman

Auto-generated profile, based on publicly available information

Aafke E. Gaartman

Department of Hematology Amsterdam UMC Location University of Amsterdam Amsterdam The Netherlands

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 April 2020 in American Journal of Hematology
Verified
Journal Article
Open access
PDF file
ENErfan Nur
Erfan Nur
AGAafke E. Gaartman
Aafke E. Gaartman
CTCharlotte F. J. van Tuijn
Charlotte F. J. van Tuijn
MTMan Wai Tang
Man Wai Tang
BBBart J. Biemond
Bart J. Biemond
Click on the book chapter title to read more.

31 January 2024 in American Journal of Hematology
Verified
Journal Article
Open access
LLLydian A. de Ligt
Lydian A. de Ligt
AGAafke E. Gaartman
Aafke E. Gaartman
BBBart J. Biemond
Bart J. Biemond
KFKarin Fijnvandraat
Karin Fijnvandraat
RBRobin van Bruggen
Robin van Bruggen
ENErfan Nur
Erfan Nur
Sickle cell disease (SCD) is an inherited hemoglobinopathy characterized by chronic hemolytic anemia and recurrent microvascular occlusions, resulting in acute painful events and progressive organ damage. Although primarily a red blood cell disorder, the pathophysiology of SCD is increasingly characterized as a complex interplay between several different cell types and cellular processes. Evidence is accumulating that neutrophils are phenotypically different in SCD and have a significant contribution in the pathophysiology of the disease. In this review, we summarize the currently available evidence on the role of neutrophils in SCD pathophysiology, demonstrating that neutrophils in SCD have an activated phenotype and play an important role in vaso‐occlusion and inflammation in SCD. Activation of neutrophils in SCD is primarily driven by hemolysis and ischemia–reperfusion injury. The ameliorating effects of treatments, for example, hydroxyurea, might be partly mediated by decreasing neutrophil counts and reversing the pro‐inflammatory properties. Whether the novel anti‐sickling therapies, reducing hemolysis, have an anti‐inflammatory effect on neutrophils, remains to be elucidated.

15 July 2021 in British Journal of Haematology
Verified
Journal Article
Open access
PDF file
AGAafke E. Gaartman
Aafke E. Gaartman
ASAjab K. Sayedi
Ajab K. Sayedi
JGJorn J. Gerritsma
Jorn J. Gerritsma
TBTim R. de Back
Tim R. de Back
CTCharlotte F. van Tuijn
Charlotte F. van Tuijn
ENErfan Nur
Erfan Nur
Summary: Intravenous fluid therapy (IV‐FT) is routinely used in the treatment of vaso‐occlusive crises (VOCs), as dehydration possibly promotes and sustains erythrocyte sickling. Patients with sickle cell disease (SCD) are at risk of developing diastolic dysfunction and fluid overload due to IV‐FT. However, data on the adverse effects of IV‐FT for VOC is sparse. We aimed to evaluate the incidence and risk factors of fluid overload due to IV‐FT in patients with SCD. Consecutive hospitalisations for VOC treated with IV‐FT between September 2016 and September 2018 were retrospectively analysed. The median (interquartile range) age was 25·0 (18·3–33·8) years and 65% had a severe genotype (HbSS/HbSβ0‐thal). Fluid overload occurred in 21% of 100 patients. Hospital stay was longer in patients with fluid overload (6·0 vs. 4·0 days, P = 0·037). A positive history of fluid overload (P = 0·017), lactate dehydrogenase level (P = 0·011), and top‐up transfusion during admission (P = 0·005) were independently associated with fluid overload occurrence. IV‐FT was not reduced in 86% of patients despite a previous history of fluid overload. Fluid overload is frequently encountered during IV‐FT for VOC. IV‐FT is often not adjusted despite a positive history of fluid overload or when top‐up transfusion is indicated, emphasising the need for more awareness of this complication and a personalised approach.

3 April 2020 in American Journal of Hematology
Verified
Journal Article
Open access
PDF file
CTCharlotte F.J. van Tuijn
Charlotte F.J. van Tuijn
AGAafke E. Gaartman
Aafke E. Gaartman
ENErfan Nur
Erfan Nur
ARAnita W. Rijneveld
Anita W. Rijneveld
BBBart J. Biemond
Bart J. Biemond
Click on the book chapter title to read more.

13 May 2022 in British Journal of Haematology
Verified
Journal Article
Closed access
AGAafke E. Gaartman
Aafke E. Gaartman
ASAnniek Strijdhorst
Anniek Strijdhorst
NENick van Es
Nick van Es
MTMan Wai Tang
Man Wai Tang
JHJarom Heijmans
Jarom Heijmans
SCSCORE consortium
SCORE consortium

6 February 2023 in American Journal of Hematology
Verified
Journal Article
Closed access
AGAafke E. Gaartman
Aafke E. Gaartman
CTCharlotte F. J. van Tuijn
Charlotte F. J. van Tuijn
ENErfan Nur
Erfan Nur
LVLiffert Vogt
Liffert Vogt
BBBart J. Biemond
Bart J. Biemond